Quarterly ResultMay 7, 2026, 04:15 PM
Verastem Q1 Net Loss $36.6M; Raises Going Concern Doubt
AI Summary
Verastem, Inc. reported a net loss of $36.6 million for the first quarter of 2026, an improvement from a $52.1 million net loss in Q1 2025, driven by $18.7 million in product revenue from AVMAPKI FAKZYNJA CO-PACK, approved in May 2025. Despite this, the company raised substantial doubt about its ability to continue as a going concern for the next twelve months, citing anticipated operating losses and the need for additional capital. Cash and cash equivalents decreased to $165.6 million from $205.0 million at year-end 2025. The company also saw increased R&D and SG&A expenses.
Key Highlights
- Net loss improved to $36.6 million in Q1 2026 from $52.1 million in Q1 2025.
- Generated $18.7 million in product revenue in Q1 2026, up from $0 in Q1 2025.
- Cash and cash equivalents decreased to $165.6 million from $205.0 million.
- Company raised substantial doubt about its ability to continue as a going concern.
- Basic net loss per share was $(0.37) in Q1 2026, compared to $(0.96) in Q1 2025.
- Research and development expenses increased to $38.2 million from $29.2 million.
- Proceeds from warrant exercises totaled $29.4 million in Q1 2026.
- Warrant liability reduced to $0 from $35.6 million due to exercise/redemption.